amide/脳卒中

The invention relates to amide and urea derivatives of the formula I in which R.sup.1 is 3-indolyl which is unsubstituted or mono- or disubstituted by A, AO, OH, Hal, CN, NO.sub.2, NH.sub.2, NHA, NA.sub.2, COA, CONH.sub.2, CONHA, CONA.sub.2, CH.sub.2 OH, CH.sub.2 OA, CH.sub.2 NH.sub.2, CH.sub.2 NHA,

The present invention relates to a novel amide compound having a glutamate receptor-inhibiting activity and salts thereof. Chemical substances in spiders which paralyze the nerve of anthropodes such as insects have been isolated and their structures have been elucidated to some extent. It has been

FIELD OF THE INVENTION This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for various behaviors. Imbalances in neuronal

FIELD OF THE INVENTION This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for various behaviors. Imbalances in neuronal

FIELD OF INVENTION This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for various behaviors. These brain networks are

BACKGROUND OF THE INVENTION Trauma to the brain or spinal cord caused by physical forces acting on the skull or spinal column, by ischemic stroke, arrested breathing, cardiac arrest, Reye's syndrome, cerebral thrombosis, cerebral embolism, cerebral hemorrhage, encephalomyelitis, hydrocephalus,

BACKGROUND OF THE INVENTION Trauma to the brain or spinal cord caused by physical forces acting on the skull or spinal column, by ischemic stroke, arrested breathing, cardiac arrest, Reye's syndrome, cerebral thrombosis, cerebral embolism, the neurological problems caused by AIDS, cerebral

FIELD OF THE INVENTION This invention is in the field of clinical neurology and relates specifically to compounds, compositions and methods for neuroprotective purposes such as controlling brain damage which occurs during periods of anoxia or ischemia associated with stroke, cardiac arrest or

FIELD OF THE INVENTION The present invention relates to antithrombotic compounds 2-alkyl aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido(3,4-b)indole-3-carboxylic acid esters/amides, pharmaceutically acceptable salts and compositions thereof useful in treatment of intravascular thrombosis such as

This application is a 371 of PCT/GB93/02130, Oct. 14, 1993. This invention relates to novel compounds having pharmacological activity, to a process for their preparation and to their use as pharmaceuticals. European Journal of Pharmacology 146 (1988 ), 187-188, and Naunyn-Schmiedeberg's Arch.

PRIORITY CLAIM This application is a .sctn.371 National Stage Application of PCT/GB2006/050353, filed on Oct. 26, 2006, which claims priority from GB Provisional Application Serial Number 0522130.4, filed on Oct. 31, 2005. BACKGROUND OF THE INVENTION In eukaryotic cells the orderly packaging of DNA

FIELD OF THE INVENTION The present invention relates to 7a-amide substituted 6,6-difluro bicyclic himbacine derivatives, which are useful as protease activated receptor-1 (PAR-1) antagonists and might be expected to be cannabinoid (CB.sub.2) receptor inhibitors. PAR-1 receptors are also known in the

FIELD OF THE INVENTION The present invention relates to novel benzamide, heteroarylamide and reverse amide, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention

The present invention relates to novel benzamide, heteroarylamide and reverse amide, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are useful in the

SUMMARY OF THE INVENTION The compounds of the present invention are antagonists of the VLA-4 integrin ("very late antigen-4"; CD49d/CD29; or .alpha.4.beta.1), the .alpha.4.beta.7 integrin (LPAM-1 and .alpha.4.beta.p), and/or the .alpha.9.beta.1 integrin, thereby blocking the binding of VLA-4 to its